Clinical Trials Search
A Phase III Comparison of Oral Capsaicin Lozenge Versus Placebo Lozenge for Radiation-Induced-Mucositis
96-92-57
- Eligibility:Click Here to View1.0) Rando d1-3 of RT
2.0) No prior RT to oral mucosa, or concomitant use of chemo - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of Adjuvant Postoperative Irradiation Combined with Cisplatin/Taxolchemotherapy Following TAH/BSO for Patients with High-Risk Endometrial Cancer
97-08
- Eligibility:Click Here to View1.0) Grade 2 or 3 with = 50% myometrial or stromal invasion of cervix or extra uterine dz confined to pelvis
2.0) PS = 70 - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Randomized Trial of Palliative Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life
97-14
- Eligibility:Click Here to View1.0) Histo proven breast or prostate malignancy.
2.0) Radiographically evidence of bone mets w/pain at that site (mets to skull, hands and feet are not elig.).
3.0) Life expect. =3 mos.
4.0) PS = 40.
5.0) BPI score >5.
6.0) No change in systemic therapy within 30 days of random.
7.0) No prior radiotherapy or palliative surgery to the painful site.
8.0) No systemic radio-isotopes (e.g. Sr89) in past 30 days.
9.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Topotecan and Paclitaxel with G-CSF (Filgrastim) Support, Alternating with Cisplatin and Etoposide in Patients with previously untreated Extensive-Stage Small Cell Lung
97-20-52
- Eligibility:Click Here to View1.0) Histo/cyto proof of SCLC
2.0) Measurable or evaluable disease.
3.0) Extensive dz (outside single RT port).
4.0) Previously untreated, except for RT, for CNS mets or SCV.
5.0) PS 0-2.
Drugs: Topotecan (provided), Taxol, G-CSF, VP-16, CDDP - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase III Trial Evaluating Low molecular Weight Heparin(LMWH) in Patients with Advanced Cancer.
97-92-51
- Eligibility:Click Here to View2.0) Life expectancy of > 12 wks.
3.0) No history of thromboembolic phenomenon such as DVT, PE, or clotted catheter (requiring anticoagulation) within the last year.
Drug: Low-Molecular Weight Heparin (LMWH) (provided)
1.0) Pt. must have histologic or cytologic evidence of breast, lung, colorectal or prostate CA, with evidence of advanced breast CA after having failed first-line chemo; or advanced lung, colorectal, or prostate having failed primary hormonal therapy. - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients with Cancer Undergoing Chemotherapy
97-92-53
- Eligibility:Click Here to View1.0) Hgb in males < 11.5, in females <10.5.
2.0) Currently receiving chemo for advanced cancer.
3.0) PS 0-1
4.0) Life expectancy >/= 6 months. - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase III Controlled Trial of Venlaflaxine in the Management of Hot Flashes
97-92-54
- Eligibility:Click Here to View1.0) Pts. with a history of breast cancer or a concern about taking estrogen for fear of getting breast cancer.
2.0) Bothersome hot flashes (>14 times per week).
3.0) Presence of hot flashes for at least one month prior to study entry.
4.0) Life expectancy >/= 6 months.
5.0) PS 0-1. - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Studye of Conventional Radiation Therapy Followed by Thalidomide for Supratentorial Glioblastoma
98-06
- Eligibility:Click Here to View
- Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Dolastatin-10 in Patients with Advanced Breast Cancer
98-32-51
- Eligibility:Click Here to View1.0) Path (+) breast ca w/clinical evidence of Measurable mets (bone-only dz are eligible)
2.0) 1 prior tx for met dz or failure w/in 6mo's of adjuvent tx- at least one tx with anthracycline or taxane
3.0) RT ok if = 25% of bone marrow - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Multicenter, Phase III Randomized, Open-label Trial for Advanced Non-Small Cell Lung Cancer (NSCLC) After Prior Platinum Based Therapy Utilizing Weekly Taxol (Paclitaxel) Versus Observation Followed by Weekly Taxol
98-800
- Eligibility:Click Here to View1.0) Recurrent or advanced NSCLC. Recurrent NSCLC must be histo. confirmed if > 1 year since initial diagnosis.
2.0) Pt. must have bidimensionally measurable lesion. (Exception for pts. who achieved a CR from prior therapy.)
3.0) Pt. must have received 4-8 cycles of induction chemo.
4.0) Pt. may not have recieved more than 2 prior regimens.
5.0) Pts. must have completed prior tx within 3-8 wks of enrollment and must begin tx in this study within 8 wks of last dose of prior chemo.
6.0) Pt. may have recieved prior taxol if given on a > 3wk schedule. - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.